Economics and health-related quality of life in antiemetic therapy: Recommendations for trial design

European Journal of Cancer

Volumn 36, Issue 12, 2000, Pages 1522-1535

  Uyl De Groot, C A ^a   Wait, S ^b   Buijt, I ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antiemetic cancer; Cost; Quality of life

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; STUDY; TREATMENT OUTCOME; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COSTS AND COST ANALYSIS; HUMANS; QUALITY OF LIFE; RESEARCH DESIGN;

EID: 0033855945     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00132-5     Document Type: Article

References (41)

1. Jönsson V., Clausen S.R., Hansen M.M. Pharmacoeconomic aspects in the treatment of curable and incurable cancer. Pharmacoeconomics. 8:1995;275-281.
2. Drummond M.F., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes. 1997;Oxford University Press, Oxford.
3. Coates A.S., Abraham S., Kaye S.B.et al. On the receiving end. patient perception of the side effects of chemotherapy Eur. J. Cancer Clin. Oncol. 19:1983;203-208.
4. Griffin A.M., Butow P.N., Coates A.S.et al. On the receiving end V. patient perceptions of the side effects of cancer chemotherapy in 1993 Ann. Oncol. 7:1996;189-195.
5. Grunberg S.M., Hesketh P.J. Control of chemotherapy-induced emesis. N. Engl. J. Med. 329:1993;1790-1796.
6. Aapro M.S. Therapeutic approach to delayed emesis. Tonato M. Antiemetics in the Supportive Care of Cancer Patients. 1996;73-77 Springer, Berlin-Heidelberg.
7. Roila F., Tonato M., Ballatori E., del Favero A. Comparative studies of various antiemetic regimens. Support Care Cancer. 4:1996;270-280.
8. Roila F., Ballatori E., Tonato M., Del Favero A. 5-HT3 receptor antagonists. differences and similarities Eur. J. Cancer. 33:1997;1364-1370.
9. Gralla R.J. Anti-emesis with cancer chemotherapy. Eur. J. Cancer. 33(Suppl. 4):1997;S63-S67.
10. Consensus conference on anti-emetic therapy. Perugia International Cancer Conference V, Perugia, 28-29 April, 1997.
11. Williams C., Coyle D., Gray A.et al. European School of Oncology advisory report to the Commission of the European Communities for the Europe Against Cancer Programme. cost-effectiveness in cancer care Eur. J. Cancer. 31A:1995;1410-1424.
12. Cox F., Hirsch J. Ondansetron. A cost-effective advance in anti-emetic therapy. Oncology. 50:1993;186-190.
13. Cunningham D., Gore M., Davidson N., Miocevich M., Manchanda M., Wells N. The real costs of emesis - an economic analysis of ondansetron versus metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur. J. Cancer. 29A:1993;303-306.
14. O'Brien B., Rusthoven J., Rocchi Q.et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs. a survey of five Canadian centres Can. Med. Assoc. J. 149:1993;296-302.
15. Sykes A.J., Kiltie A.E., Stewart A.L. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting. a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy Support Care Cancer. 5:1997;500-503.
16. Zbronek A., Cantor S.B., Cardenas M.P., Hill D.P. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am. J. Hosp. Pharm. 51:1994;1555-1563.
17. Plosker G.L., Milne R.J. Ondansetron - a pharmacoeconomic and quality of life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Pharmacoeconomics. 2:1992;285-302.
18. Jones A.L., Lee G.J., Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur. J. Cancer. 29A:1993;51-56.
19. Ballatori E., Roila F., Berto P.et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens. a hospital perspective from Italy Pharmacoeconomics. 5:1994;227-237.
20. Gandara DR, Edelman MJ, Perez EA. 5HT3 antagonists in the prevention of actue emesis from cisplatin: issues of dose, schedule and route. In: MASCC Consensus conference on anti-emetic therapy. Perugia International Cancer Conference V, Perugia, 28-29 April, 1997.
21. Peters M.D., Long K.S., Patel H.S.et al. Multicentre evaluation of ondansetron use in hospitalized oncology patients. Am. J. Hosp. Pharm. 50:1993;1164-1170.
22. McQueen K.D., Milton J.D. Multicentre post-marketing surveillance of ondansetron therapy in pediatric patients. Ann. Pharmacother. 28:1994;85-92.
23. Technology Assessment Centre. Technology Report: Results of the UHC Ondansetron Multicentre Drug Use Evaluation. Oak Brook, IL, University Hospital Consortium, 1993.
24. Swinbourne A.L., Tattersall M.H.N. Patient's point of view. Dicato M. Medical Management of Cancer Treatment - Induced Emesis. 1998;195-203 Blackwell Science, Oxford.
25. Grunberg S.M. Economic impact of emesis. Oncology. 9:1995;S155-S160.
26. Grunberg S.M., Boutin N., Ireland A., Miner S., Silveira J., Ashikaga T. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 4:1996;435-439.
27. Osoba D., Zee B., Warr D., Kaizer L., Latreille J., Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology. 53:1996;92-95.
28. Osoba D., Zee B., Pater J.et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J. Clin. Oncol. 15:1997;116-123.
29. Crucitt M.A., Hyman W., Grote T.et al. Efficacy and tolerability of oral ondansetron versus prochlorepazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin. Ther. 18:1996;778-788.
30. Bruntsch U., Drechsler S., Eggert J.et al. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Semin. Oncol. 21:1994;7-11.
31. Clavel M., Soukop M., Greenstreet Y.L.A. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology. 50:1993;180-185.
32. Clavel M, Bonneterre J, d'Allens H, Paillarse JM and the French Ondansetron Study Group. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer 1995, 31A, 15-19.
33. Soukop M., McQuade B., Hunter E.et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 49:1992;295-304.
34. Berry W.R., House K.W., Lee J.T., Plagge P.B., Meshad M.W., Grapski R. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. Semin. Oncol. 19:1992;S33-S37.
35. Garbe C., Drechsler S., Fiedler H.et al. Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. Semin. Oncol. 5:1994;12-16.
36. 3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer. 73:1994;445-454.
37. Barrenetxea G., Schneider J., Centeno M.M.et al. Chemotherapy-induced emesis. management of early and delayed emesis in milder emetogenic regimens Cancer Chemother. Pharmacol. 38:1996;471-475.
38. Lindley C.M., Hirsch J.D., O'Neill C.V., Transau M.C., Gilbert C.S., Osterhaus J.T. Quality of life consequences of chemotherapy-induced emesis. Qual. Life Res. 1:1992;331-340.
39. Pater J.L., Lofters W.S., Zee B.et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann. Oncol. 8:1997;181-185.
40. Haes J.C.J.M. de, Knippenberg F.C.E van, Neijt J.P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br. J. Cancer. 62:1990;1034-1038.
41. Aaronson N.K., Ahmedzai S., Bergman B.et al. The European Organisation for Research and Treatment of Cancer QLQ-C30. a quality of life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85:1993;365-376.